Am­gen re­searchers con­firm the lack­lus­ter da­ta on the KRAS G12C drug AMG 510 re­port­ed at ES­MO — but they still have a long way to go ex­plor­ing op­tions

We learned at ES­MO that Am­gen’s star can­cer drug, the pi­o­neer­ing KRAS G12C play­er AMG 510, tend­ed to­ward the unim­pres­sive when ap­plied out­side non-small cell lung can­cer. And the re­search team has an­oth­er batch of da­ta to back that up for AS­CO.

In their Code­Break100 study, in­ves­ti­ga­tors re­port­ed on 25 pa­tients with ad­vanced tu­mors out­side of both NSCLC and col­orec­tal can­cer. Among those, they tracked 22 pa­tients for 7 weeks or longer and found 3 con­firmed par­tial re­spons­es (1 ap­pen­diceal, 1 melanoma and 1 en­dome­tri­al tu­mor). Thir­teen had sta­ble dis­ease and the rest pro­gressed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA